BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)
February 28, 2025
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)
Karin A. Orvis Chief Statistician of the United States Statistical and Science Policy Branch Chief Office of Information and Regulatory Affairs (OIRA) Office of Management and Budget (OMB)
Dear Ms. Orvis, The Biotechnology Innovation Organization (BIO) welcomes this opportunity to respond to the request for public comment from the Office of Management and Budget (OMB), on behalf of the Economic Classification Policy Committee (ECPC), as a part of the review of the 2022 North American Industry Classification System (NAICS) for potential revisions to be made to the structure and content of the NAICS for 2027.
BIO represents more than 1,000 members in a biotech ecosystem with a central mission — to advance public policy that supports a wide range of companies and academic research centers — that are working to apply biology and technology in the agriculture, energy, manufacturing, and health sectors to improve the lives of people and the health of the planet. BIO is committed to speaking up for the millions of families around the globe who depend upon our success.
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)
Karin A. Orvis
Chief Statistician of the United States
Statistical and Science Policy Branch Chief
Office of Information and Regulatory Affairs (OIRA)
Office of Management and Budget (OMB)
Dear Ms. Orvis,
The Biotechnology Innovation Organization (BIO) welcomes this opportunity to respond to the request for public comment from the Office of Management and Budget (OMB), on behalf of the Economic Classification Policy Committee (ECPC), as a part of the review of the 2022 North American Industry Classification System (NAICS) for potential revisions to be made to the structure and content of the NAICS for 2027.
BIO represents more than 1,000 members in a biotech ecosystem with a central mission — to advance public policy that supports a wide range of companies and academic research centers — that are working to apply biology and technology in the agriculture, energy, manufacturing, and health sectors to improve the lives of people and the health of the planet. BIO is committed to speaking up for the millions of families around the globe who depend upon our success.